195 related articles for article (PubMed ID: 7531589)
21. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
Pollack A; Zagars GK; el-Naggar AK; Terry NH
Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
Oosterom R; Bogdanowicz J; Schröder FH
Eur Urol; 1989; 16(4):253-7. PubMed ID: 2475344
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age.
Shockley KF; Maatman TJ; Carothers GC; Warzynski MJ
Prostate; 1996 Jul; 29(1):46-50. PubMed ID: 8685055
[TBL] [Abstract][Full Text] [Related]
24. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer.
Stock RG; Stone NN; Ianuzzi C; Unger P
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):815-21. PubMed ID: 7591888
[TBL] [Abstract][Full Text] [Related]
25. [Usefulness of prostate-specific antigen in the diagnosis of lymphatic metastases in cancer of the prostate].
Saad F; Bertrand P; Paquin JM; Péloquin F
Ann Chir; 1995; 49(8):680-4. PubMed ID: 8561420
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen and prostate acid phosphatase in the detection of early prostate cancer and the prediction of regional lymph node metastases.
Wirth MP; Frohmüller HG
Eur Urol; 1992; 22(1):27-32. PubMed ID: 1385142
[TBL] [Abstract][Full Text] [Related]
27. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H
J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
[TBL] [Abstract][Full Text] [Related]
28. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?
Cheng L; Leibovich BC; Bergstralh EJ; Scherer BG; Pacelli A; Ramnani DM; Zincke H; Bostwick DG
Cancer; 1999 Jun; 85(11):2455-9. PubMed ID: 10357418
[TBL] [Abstract][Full Text] [Related]
29. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer.
Narayan P; Fournier G; Gajendran V; Leidich R; Lo R; Wolf JS; Jacob G; Nicolaisen G; Palmer K; Freiha F
Urology; 1994 Oct; 44(4):519-24. PubMed ID: 7524237
[TBL] [Abstract][Full Text] [Related]
30. Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy.
Stege RH; Tribukait B; Carlström KA; Grande M; Pousette AH
Prostate; 1999 Feb; 38(3):183-8. PubMed ID: 10068342
[TBL] [Abstract][Full Text] [Related]
31. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group.
van den Ouden D; Tribukait B; Blom JH; Fossa SD; Kurth KH; ten Kate FJ; Heiden T; Wang N; Schroder FH
J Urol; 1993 Aug; 150(2 Pt 1):400-6. PubMed ID: 8326563
[TBL] [Abstract][Full Text] [Related]
32. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
[TBL] [Abstract][Full Text] [Related]
33. Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer.
Sands ME; Zagars GK; Pollack A; von Eschenbach AC
Urology; 1994 Aug; 44(2):215-20. PubMed ID: 7519381
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
35. Expression of p27kip1 in prostatic adenocarcinoma.
Cheville JC; Lloyd RV; Sebo TJ; Cheng L; Erickson L; Bostwick DG; Lohse CM; Wollan P
Mod Pathol; 1998 Apr; 11(4):324-8. PubMed ID: 9578081
[TBL] [Abstract][Full Text] [Related]
36. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Saeid MS; Young CY; Klee GG; Tindall DJ; Bostwick DG
Urology; 1999 May; 53(5):939-44. PubMed ID: 10223487
[TBL] [Abstract][Full Text] [Related]
37. Correlation of serum prostate specific antigen and quantitative immunohistochemistry.
Weir EG; Partin AW; Epstein JI
J Urol; 2000 Jun; 163(6):1739-42. PubMed ID: 10799172
[TBL] [Abstract][Full Text] [Related]
38. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
Gustafsson O; Norming U; Gustafsson S; Eneroth P; Aström G; Nyman CR
Br J Urol; 1996 Mar; 77(3):433-40. PubMed ID: 8814852
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.
Ross JS; Sheehan CE; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman RP; Fisher HA; Rifkin MD; Muraca PJ
Cancer; 1997 Jun; 79(11):2162-70. PubMed ID: 9179063
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
Zagars GK; Pollack A; von Eschenbach AC
Cancer; 1997 Apr; 79(7):1370-80. PubMed ID: 9083160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
